Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions
Ovarian Cancer · HGSOC · HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital, Cambridge, United Kingdom
The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
St. James's University Hospital, Leeds, United Kingdom
University Hospitals of Leicester NHS Trust -Leicester Royal Infirmary, Leicester, United Kingdom
University College London Hospitals NHS Foundation Trust - Cancer Clinical Trials Unit, London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London, United Kingdom
Royal Marsden NHS Foundation Trust - Royal Marsden Hospital, London, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust - Royal Preston Hospital, Preston, United Kingdom
Royal Marsden NHS Foundation Trust - Institute of Cancer Research, Sutton, United Kingdom
Study leads
Susana Banerjee, MBBS MA FRCP PhD
Principal Investigator
Royal Marsden NHS Foundation Trust